(177)Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma

Patients with non-Hodgkin lymphoma (NHL) who are treated with rituximab may develop resistant disease, often associated with changes in expression of CD20. The next-generation β-particle–emitting radioimmunoconjugate (177)Lu-lilotomab-satetraxetan (Betalutin) was shown to up-regulate CD20 expression...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Nucl Med
Main Authors: Malenge, Marion M., Patzke, Sebastian, Ree, Anne H., Stokke, Trond, Ceuppens, Peter, Middleton, Brian, Dahle, Jostein, Repetto-Llamazares, Ada H.V.
Formato: Artigo
Idioma:Inglês
Publicado em: Society of Nuclear Medicine 2020
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7539655/
https://ncbi.nlm.nih.gov/pubmed/32245896
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.119.237230
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados